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The development of new asthma biologics and receptor blockers for the treatment of paediatric 
severe asthma raises challenges. It is unclear whether there are sufficient children in Europe to 
recruit into randomised placebo-controlled trials to establish efficacy and safety in this age group.
In February 2016, the European Respiratory Society funded a clinical research collaboration 
entitled “Severe Paediatric Asthma Collaborative in Europe” (SPACE). We now report the SPACE 
protocol for a prospective pan-European observational study of paediatric severe asthma. Inclusion 
criteria are: 1) age 6–17 years, 2) severe asthma managed at a specialised centre for ≥6 months, 
3) clinical and spirometry evidence of asthma, and 4) reaching a pre-defined treatment threshold. 
The exclusion criterion is the presence of conditions which mimic asthma symptoms. Eligible 
children will be prospectively recruited into a registry, recording demographics, comorbidities, 
quality of life, family history, neonatal history, smoking history, asthma background, investigations, 
and treatment. Follow-up will provide longitudinal data on asthma control and treatment changes.
The SPACE registry, by identifying well-phenotyped children eligible for clinical trials, and the 
amount of overlap in eligibility criteria, will inform the design of European trials in paediatric severe 
asthma, and facilitate observational research where data from single centres are limited.
j.grigg@qmul.ac.ukNorrice M. Liu1, Wim van Aalderen1, Karin C.L. Carlsen1, Courtney Coleman1, 
James D. Chalmers1, Steve Cunningham1, Ricardo M. Fernandes1, Louise J. Fleming1, 
Monika Gappa1, Bülent Karadag1, Fabio Midulla1, Marielle W.H. Pijnenburg1, 
Niels W. Rutjes1, Franca Rusconi  1, Jonathan Grigg1
Introduction
In order to deliver new treatments to children and 
adolescents with severe asthma, clinical trials of 
new biologics and receptor blockers are needed, 
since data on safety and efficacy from trials in adults 
cannot always be appropriately extrapolated to 
this age group. There are however problems with 
performing clinical trials in children and adolescents 
with asthma. For example, severe asthma 
phenotypes are less well characterised, the severity 
of paediatric asthma tends to vary greatly, numbers 
are fewer than in adult asthma, long-term adverse 
effects may be more important, and children and 
adolescents often engage less well with complex 
clinical trial interventions than adults [1]. Indeed, 
it is currently unclear whether the subphenotypes 
and putative endotypes of asthma eligible for some 
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of the new monoclonal treatments even exist in 
children with severe asthma and whether there 
are sufficient children to support multiple trials in 
Europe with overlapping eligibility criteria. In 2015, 
the European Medicines Agency (EMA) expressed 
their view to officers of the Paediatric Assembly 
of the European Respiratory Society (ERS), that 
recruitment of children with asthma into trials 
of new biologics would be significantly enhanced 
if there were a network of European respiratory 
paediatricians able to both support recruitment 
and provide academic advice and guidance to 
the EMA and industry. In 2015, the ERS funded a 
clinical research collaboration (CRC), developed by 
members of its Paediatric Assembly (Assembly 7) 
to develop the evidence and structures to enable 
European paediatricians to identify and recruit 
eligible children. Funding of CRCs is a major route 
whereby the ERS engages in the promotion and 
coordination of activities in respiratory medicine 
by working to advance science and clinical research 
within a specific disease area (www.ersnet.org/
research/clinical-research-collaborations). The 
aim of this CRC entitled “Severe Paediatric Asthma 
Collaborative in Europe” (SPACE) is to: 1) develop 
a minimum “core” eligibility criteria dataset which 
will identify children and adolescents with genuine 
severe asthma as per ERS/American Thoracic 
Society (ATS) taskforce guidelines, and by using this 
dataset, prospectively survey the number of children 
eligible for current and proposed trials; 2) develop 
a bid for a registry of eligible children to not only 
enhance participation in trials but also generate 
new insights into responsive subgroups; and 
3) actively engage with children and adolescents 
to help understand how to better promote trial 
opportunities and remove barriers to involvement 
in therapeutic clinical trials of new severe asthma 
treatments. Here we report the protocol for the 
SPACE registry, an open, pan-European registry of 
paediatric patients with severe asthma.
Study objectives
The objectives of SPACE are as follows.
●● To develop a pan-European multicentre, 
prospective and observational registry of children 
with severe asthma, incorporating baseline and 
annual follow-up data.
●● To agree upon common definitions and registry 
entry criteria across Europe. The registry will 
record the demographics, comorbidities, 
aetiology, treatment, resource use, exacerbations, 
severity and prognosis of severe paediatric asthma 
across Europe; providing a comprehensive real-
life description of the characteristics and burden 
of severe paediatric asthma across Europe.
●● To provide a database of well-phenotyped 
paediatric patients with true severe asthma and 
to develop an infrastructure to support trials of 
new therapies in paediatric asthma (especially 
biologics), aimed at increasing participation of 
European children in these trials, enhancing 
participation of ERS paediatricians, children with 
severe asthma and their families in the planning 
of future studies, and generating new academic 
insights into target populations.
Protocol development
The SPACE registry is based on the successful 
ERS CRC for Bronchiectasis (EMBARC), a registry 
supported by the Health Informatics Centre (HIC) 
at the University of Dundee (Dundee, UK) [2]. With 
their support and close liaison, the SPACE protocol 
was developed following thorough discussions 
amongst leading respiratory paediatricians from 
Germany, Italy, the Netherlands, Norway, Portugal, 
Turkey and the UK.
The CRC initially set up a core group to 
systematically review the literature on proposed 
definitions of severe paediatric asthma (details 
on the methods of the systematic review will be 
reported separately). Based on the pre-selected 
variables and eligibility criteria, a prototype of the 
registry was developed.
Registry
The SPACE registry will be a prospective, non-
interventional, observational cohort study, with a 
short-term target of enrolling 7–20 patients per 
centre over the course of the first year. Enrolment 
is planned to increase with time and future funding. 
Study centres will be invited to participate on the 
basis of their ability to include patients from a 
severe asthma clinic or service, and a track record 
of contributing to clinical research. Consideration 
will be given to encourage investigators from 
under-represented parts of Europe (such as Eastern 
Europe) to contribute, making this a representative 
and truly pan-European registry.
Asthma management will be according to local 
policies with no additional intervention from the 
study. The registry will thereby identify differences 
in practice at various European countries. Children 
and their parents will provide assent and consent 
for data collection at enrolment (detailed later 
in this article) and follow-up, in line with local 
regulations.
Local principle investigators will be practising 
paediatric respiratory consultants in tertiary or 
specialised units. The initial phase is planned as 
a 1-year prospective survey including recruitment 
and data collection. This will generate data for 
the first cross-sectional analysis. Should future 
funding allow, prospective data will be collected 
with a follow-up phase which will comprise annual 
follow-ups. This will provide longitudinal data on 
any changes in asthma control and treatments. 
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Enrolment and number of participating centres 
and countries may also expand. We designed the 
ethics approval (detailed later) to include any future 
expansion.
Participants
Eligible participants are identified using the 
inclusion and exclusion criteria (tables 1 and 2).
Recruitment of children
Parents and children will be invited to participate in 
the registry during routine clinical encounters and 
will be screened for eligibility using the inclusion 
and exclusion criteria defined above. If patients 
are eligible, they and their parents will be provided 
with a copy of the patient information sheet and 
the parent information sheet which will provide 
details of the registry aims and the type of clinical 
information collected. Children and their parents 
will be asked to provide written informed assent 
and consent following ample time to consider 
participation.
Participants and their parents will be informed 
and will be required to agree to their medical 
records being inspected by the investigators or 
their delegate, if required, but understand that their 
confidential details will not be disclosed outside 
the research team, as non-identifiable data will 
be stored within the database. The participant will 
receive a copy of the consent and assent forms and 
a copy will be filed in their medical notes.
Data collection
Data will be collected on two or more occasions. 
1) Case report form: the baseline dataset at 
enrolment, incorporating all relevant paediatric severe 
asthma variables. 2) Annual review form: if funding 
allows, follow-up data collected annually (±3 months), 
signifying changes in medications, exacerbations, 
hospital admissions and survival status.
The dataset is sufficiently simple that any 
specialist asthma clinic will be able to provide the 
data. Nevertheless, the data are sufficiently robust 
that they will provide a comprehensive overview 
of all aspects of paediatric severe asthma care in 
Europe. The data fields were established following 
consultation with European stakeholders. There will 
be an option for participants to consent for future 
contact concerning participation in future clinical 
studies. The network will therefore aid research 
collaborations around Europe. Figure 1 shows part 
of the online data collection platform.
An adherence assessment along with data 
on comorbidities, risk factors for asthma, family 
history, neonatal history and smoking history will 
be recorded. The Paediatric Asthma Quality of Life 
Questionnaire score will be incorporated into the 
registry.
Asthma background information
Lung function
Best and worst pre- and post-bronchodilator 
spirometry results in the past 6 months will be 
recorded. Spirometry will be performed according 
to the ATS/ERS standards [3]. The Global Lung 
Function Initiative-2012 equations will be used to 
generate predicted values, lower limits of normal 
and z-scores for spirometric indices.
The results of bronchial provocation tests, if 
applicable, may be recorded.
Table 1 Inclusion and exclusion criteria for SPACE registry participants
Inclusion criteria
 Age 6–17 years
 Diagnosis confirmed, evaluated and managed at a specialised centre for 
≥6 months
 Symptoms
  Wheeze heard by trained healthcare professional OR
  Self-reported wheeze in the past 12 months
 Spirometry evidence of asthma
  Bronchial obstruction with bronchodilator reversibility ≥12% OR
  Bronchial provocation test with ≥10% fall in FEV1
 Treatment
  High-dose inhaled corticosteroids (table 2) for ≥6 months +  
long-acting β-agonist/leukotriene modifier OR
  Systemic corticosteroids for ≥25% of the past 12 months
Exclusion criteria
 Symptoms are primarily due to the following conditions, which might 
mimic asthma
  Allergic bronchopulmonary aspergillosis
  Bronchiolitis obliterans
  Cystic fibrosis
  Primary ciliary dyskinesia
  Significant bronchiectasis (not related to asthma)
  Severe immunodeficiency/immunosuppression
  Central airway obstruction, or compression
  Congenital airway malformation (e.g. vascular ring)
  Foreign body
  Tracheobronchomalacia
  Interstitial lung disease
  Lobectomy
  Other pulmonary surgery
  Carcinoid or other tumour
  Congenital heart disease
  Connective tissue disease
  Neuromuscular diseases 
FEV1: forced expiratory volume in 1 s.
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Asthma investigations
The most recent results for: exhaled fractional nitric 
oxide; sputum and blood eosinophil counts; total 
IgE, specific IgE and skin prick test; radiology and 
bronchoscopy findings including bronchoalveolar 
lavage cytology and microbiology will be recorded, 
if available.
Asthma control
Asthma control will be assessed by Asthma Control 
Questionnaire and/or Asthma Control Test scores 
within 4 weeks of enrolment, along with a Global 
Initiative for Asthma assessment. The number of 
exacerbations (episodes requiring systemic steroids), 
hospital admissions, and incidents of noninvasive 
or ventilatory support in the past 12 months will be 
documented. Total number of intensive care unit 
admissions and mechanical ventilation since the 
diagnosis of asthma will also be recorded.
Treatment
Details on various inhaled and oral therapies 
(bronchodilators, steroids, anticholinergic, 
leukotriene receptor antagonist, antihistamines, 
anti-reflux medications, theophylline, antibiotics 
and monoclonal antibody) will be recorded. Further 
details on the monoclonal antibody treatments 
including previous assessment, usage and reasons 
for discontinuation will be documented. Any adverse 
effect of chronic steroid use will also be noted. 
Treatment options will be regularly updated as 
new treatments become available during the study.
Ethics, governance, data access and 
quality control
This study received ethical approval from the London 
(Bloomsbury) Research Ethics Committee in the UK 
on February 20, 2018 (18/LO/0178). The registry 
was developed according to recommendations 
made by the EPIRARE (European Platform for Rare 
Disease Registries) consortium [4] and EUCERD on 
registries in the European Union [5].
The registry is secured at the HIC at the University 
of Dundee. The Safe Haven model (www.scot-ship-
toolkit.org.uk/information-page/ship-safe-havens) 
will provide anonymous registry data to researchers 
throughout Europe. The Safe Haven is a virtual 
desktop allowing for secure data access and analysis; 
data security is ensured by inhibition of data copying 
or downloading. Local data access will be unrestricted 
to active investigators and other stakeholders. The 
joint chief investigators and the steering committee 
have a download facility to enable quality checks and 
data review. Missing data will be highlighted to the 
investigators and a random audit will be conducted 
at study sites. Annual summaries of the study may 
be presented at conferences or used for clinical or 
scientific publications.
Requests to access or analyse the database will 
be submitted to the SPACE scientific committee.
The HIC database and governance processes 
surrounding data management and access are fully 
compliant with the UK Data Protection Act 1998 
and the Data Protection Directive 95/46/EC of the 
European Parliament and of the Council (1995), 
and will also comply with the new EU General Data 
Protection Regulation from May 2018. Data sharing Figure 1 The SPACE registry data collection platform.
Table 2 Definition of high-dose inhaled corticosteroids for inclusion criteria
Inhaled corticosteroid Dose μg Inhaler type
Beclomethasone ≥800 DPI, CFC MDI
≥320 HFA MDI
Budesonide ≥800 MDI, DPI
Ciclesonide ≥160 HFA MDI
Fluticasone ≥500 HFA MDI, DPI
Fluticasone furoate ≥200 DPI
Fluticasone propionate ≥400 DPI
≥500 HFA
Mometasone ≥500 DPI
Triamcinolone ≥1200  
DPI: dry powder inhaler; MDI: metered-dose inhaler; CFC: chlorofluorocarbon; 
HFA: hydrofluoroalkane.
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agreements will be established between sites and 
the HIC, warranting compliance with national laws 
on ethics and data protection.
The study will be conducted in line with Good 
Clinical Practice. A favourable ethical opinion will 
be obtained, if applicable, by each site from the 
appropriate research ethics committee or institutional 
review board. All patients, or their parents for those 
under the age of 16 years, must provide written 
informed consent prior to participation.
Patient involvement
The European Lung Foundation (ELF) (www.
europeanlung.org) is working with the SPACE 
network to ensure appropriate patient consultation 
across Europe. The registry and relevant documents 
were developed with the review and feedback from 
the patient advisory group. Members of the ELF and 
patient advisory group form part of the steering 
committee of the SPACE registry. With the help 
of ELF, patient information resources in multiple 
languages will be established.
Discussion
The proposed protocol has strengths and limitations. 
Its strengths are: 1) the wide range of participating 
specialised centres across Europe (table 3), with 
the capacity to provide a good representation of 
well-phenotyped children for future pan-European 
studies; 2) its close link with the ERS CRC EMBARC, 
which has proven to be a successful international 
registry and serves as a guide for the development of 
SPACE; 3) participation of industrial representatives 
(from GlaxoSmithKline and AstraZeneca via 
previous links with CRC members) who provided 
advice on the development of this registry, and are 
the industry links for the development of clinical 
trials; and 4) its link with patient organisations, 
the supporting documents for the registry were 
developed with the support of ELF and their patient 
advisory group, which consists of adult patients who 
have had severe asthma from a young age and 
the parents of children with severe asthma. The 
registry’s limitations are that: 1) the initial cross-
sectional data analysis is not reflective of all major 
European centres managing severe asthma; 2) the 
lack of paediatric patient representatives and limited 
representation from outside northern Europe; 3) no 
current direct industry funding; and 4) no long term 
funding. The future work of SPACE will both address 
these limitations, and develop an analysis plan for 
data from the initial cross-sectional data collection.
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Key points
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●● SPACE has developed a protocol for a pan-European registry for 
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●● The SPACE registry will facilitate observational research as well as 
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